Table 2 Significantly overexpressed genes in early fracture tissue. The columns Gene and UniGene show the symbol and UniGene cluster id for the human ortholog of the sheep gene in question. See Methods for abbreviations. The genes are ordered according to Benjamini-Hochberg (BH)-corrected p-value. EST Ratio shows the EST counts from PF7/PF10 vs. the counts in the resting human bone libraries; the adjusted count ratio is given in parentheses followed by the BH-corrected p-value. The adjusted count ratio was calculated by the formula ad/bc, where a was the count of a given gene in the PF7/PF10 libraries, b the total count of ESTs in PF7/PF10, c the count of the gene in the human EST libraries, and d the total count of ESTs in the human libraries. That is, the EST counts of individual genes were corrected for the total number of ESTs in the EST libraries to provide information about the relative abundance of ESTs corresponding to a given gene. RT-PCR summarizes the statistical analysis of the RT-PCR results for the comparison between PF7 and PF10 (first entry), among PF7, PF10, and PF14 (second entry), and among PF7, PF10, PF14, and PF42 (third entry). '-' indicates non-significant, '*' indicates an adjusted p-value of 0.05 > p > 10^-4, and "**" indicates a p-value less than 10^-4. "n.d.", not done. A complete list of absolute fold change values for all genes is available in the online supplement. Bone/Development indicates whether the gene in question has previously been shown to be involved in bone development or fracture healing (first entry) or development (second entry). See Methods for the abbreviations. §No values were available for the 14d time point for FTH1.

EEF1A1

Hs.522463

664:32 (4.3; p = 5.7 × 10^-21)

-/*/**

+/+ [60]

COX1

Hs.550345

265:0 (-;p = 4.0 × 10^-19)

n.d.

-/+ [61]

RPLPO

Hs.448226

278:1 (57; p = 1.3 × 10^-18)

-/**/**

-/-

COL1A1

Hs. 172928

1987:249(1.6; p = 5.3 × 10^-13)

*/**/**

+/+ [62]

Osteonectin

Hs.111779

588:39(3.1; p = 2.9 × 10^-12)

-/*/**

+/+ [63]

RPS2

Hs.506997

268:7 (7.9; p = 8.6 × 10^-12)

*/**/**

-/-

FTH1^§

Hs.558804

332:14 (4.9; p = 3.7 × 10^-11)

-/-/**

+/+ [60]

RPL3

Hs.119598

179:1 (37; p = 4.4 × 10^-11)

-/*/**

-/+ [64]

LAMR1

Hs.558354

221:4 (11; p = 4.9 × 10^-11)

-/**/**

+/+ [11]

UBC

Hs.520348

190:3 (13; p = 8.5 × 10^-10

*/**/**

-/-

ITM2C

Hs.111577

114:0 (-;p = 1.4 × 10^-7)

-/**/**

+/+ [42]

COL3A1

Hs.443625

444:42 (2.2; p = 1.8 × 10^-5)

-/**/**

-/+ [65]

EEF2

Hs.515070

85:0(-;p = 2.9 × 10^-5)

-/**/**

-/+ [66]

COL4A1

Hs.17441

105:2 (11; p = 9.5 × 10^-5)

-/*/*

-/+ [67]

RPL7A

Hs.558380

78:0(-;p = 9.6 × 10^-5)

-/*/**

-/+ [68]

K- ALPHA- 1

Hs.334017

89:1 (18; p = 0.00016)

*/**/**

-/-

ACTA1

Hs.1288

72:0 (-;p = 0.00021)

*/**/**

-/-

SLC25A6

Hs.350927

71:0(-;p = 0.00032)

-/**/**

-/+ [69]

EIF4A1

Hs. 129673

82:1(17; p = 0.00047)

n.d.

-/-

HMOX1

Hs.517581

66:0 (-;p = 0.00066)

*/**/**

-/+ [41]

FTL

Hs.433670

63:0 (-; p = 0.00096)

-/*/**

-/+ [70]

RPL7

Hs.421257

63:0 (-; p = 0.00096)

-/**/**

-/-

ACP5

Hs.1211

58:0 (-;p = 0.0019)

*/**/**

+/+ [71]

SERPINH1

Hs.241579

154:10 (3.2; p = 0.0038)

*/**/**

+/+ [22]

GNAI2

Hs.77269

52:0 (-; p = 0.0072)

-/**/*

-/+ [72]

RPS5

Hs.378103

62:1 (18; p = 0.0080)

n.d.

-/-

EIF5A

Hs.534314

73:2 (7.5; p = 0.0083)

n.d.

-/-

RPS3

Hs.546286

50:0 (-;p = 0.0089)

-/**/**

-/-

MMP14

Hs.2399

47:0 (-;p = 0.013)

**/**/**

+/+ [73]

APOE

Hs.515465

47:0 (-; p = 0.013)

-/-/*

-/-

ENO1

Hs.517145

146:11 (2.7; p = 0.017)

n.d.

+/+ [60]

HLA-A

Hs.181244

88:4 (4.5; p = 0.018)

n.d.

-/-

KARS

Hs.3100

44:0 (-;p = 0.019)

-/*/*

-/-

Basigin

Hs.501293

45:0 (-;p = 0.019)

-/*/**

-/+ [74]

CD74

Hs.436568

56:1 (11; p = 0.024)

n.d.

-/+ [75]

RPL10

Hs.401929

43:0 (-; p = 0.025)

-/**/**

+/+ [76]

PGK1

Hs.78771

54:1 (11; p = 0.026)

n.d.

-/-

FCGRT

Hs.111903

40:0 (-;p = 0.031)

-/*/**

-/-

NSEP1

Hs.512451

50:1 (10; p = 0.036)

n.d.

-/+ [77]